« Back
Home /
CDK9-IN-2

CDK9-IN-2

Item no.	HY-16462-5mg
Manufacturer	MedChem Express
CASRN	1263369-28-3
Amount	5 mg
Quantity options	10mM/1mL 10 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Heart & Blood Cancer Lymphatic System Cancer
Type	Inhibitors
Clone	N/A
Specific against	other
Purity	99.37
Formula	C23H25ClFN5
Citations	[1]Michel Faure, et al. Pharmacodynamic markers associated with cyclin-dependent kinase inhibitors. From PCT Int. Appl. (2012), WO 2012131594A1
Smiles	ClC1=CN=C(N[C@@H]2CC[C@@H](N)CC2)C=C1C3=NC(NCC4=CC(F)=CC=C4)=CC=C3
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	1263369-28-3
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-anti-virus
Manufacturer - Targets	CDK
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	425.93
Product Description	CDK9-IN-2 is a special cyclin-dependent kinase 9 (CDK9) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC50 of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively.
Manufacturer - Research Area	Cancer
Solubility	DMSO : 50 mg/mL (ultrasonic)
Manufacturer - Pathway	Cell Cycle/DNA Damage
Isoform	CDK9
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-16462-5mg-safety-datasheet.pdf